



June 7, 2024

New Product Registered to Micron's INDICATE Program Building Bridges between Therapeutics and Diagnosis

-Acer Medical's AI Diagnostic Software for Bone Mineral Density Abnormalities and Ophthalmologic Diseases-


Micron, Inc. (hereafter, "Micron," head office: Tokyo) is pleased to announce that two new products from Acer Medical Inc. (hereafter, "Acer Medical," head office: Taipei) have been added to "INDICATE Building Bridges between Therapeutics and Diagnosis," bringing the total number registered to three from Acer Medical. This registration is expected to contribute to the development of medical care by expanding opportunities for clinical trials and research using artificial intelligence (AI) diagnostic software for abnormal bone mineral density using chest X-ray images, age-related macular degeneration (AMD), and diabetic retinopathy (DR) using fundus images.

Acer Medical, founded in 2018, is the first subsidiary under the Acer Group providing AI-assisted medical imaging and preventive medicine by integrating medical software and hardware solutions. The company aims to promote interdisciplinary collaborations with medical and healthcare sectors to increase health awareness, disease prevention, and medical care.

The AI diagnostic software developed by Acer Medical (VeriOsteo OP, VeriSee AMD, VeriSee DR) is used to quickly identify high-risk patients of various disease areas and lead to referrals to specialists in each field. VeriSee DR is approved as a medical device in Taiwan, Thailand, Malaysia, Philippines, and Indonesia, and has already been validated and used in more than 200 hospitals.

Disease Areas

VeriOsteo OP: Osteoporosis, bone mineral density loss VeriSee AMD: Eye disease, age-related macular degeneration (AMD) VeriSee DR: Eye disease, diabetic retinopathy (DR)



The report of AI-assisted Diagnostic Software - VeriSee AMD

For further information on the products, please see below: https://www.acer-medical.com/

Since its establishment, Micron has been contributing to healthcare by approaching medical imaging from both the diagnostic and therapeutic perspectives. The new project "INDICATE" (\underline{IN} novative \underline{DI} agnostic \underline{C} apabilities \underline{A} doption \underline{T} o \underline{E} nd-users delivers innovative technology to your doorstep) was launched with the theme of "Bridging the gap between SaMD (Software as Medical Device) and diagnostic technologies." In this project, we are introducing and proposing image analysis technologies that incorporate AI and other advanced technologies. We will be a bridge between domestic and foreign companies that want to introduce SaMD in Japan, and pharmaceutical companies and medical device companies that are interested in advanced technologies. We will continue to contribute to the development of digital healthcare technologies related to medical imaging.

Chairman & CEO	Allen Lien, MD, DrPH
Head Office	No. 86, Sec. 1, Xintai 5th Rd., Xizhi Dist., New Taipei City, Taiwan
Established	April 25, 2018
Business Scope	\cdot Development, manufacture, and sale of medical devices with AI
	· Medical AI engineering service provider
	\cdot Development, manufacture, and sale of telehealth systems and platforms
URL	https://www.acer-medical.com/

Acer Medical Inc. Company Information

Micron, Inc.

President	Hiroaki Suzuki
Head Office	3-13-16 Mita, Minato-ku, Tokyo, Japan
Established	October 3, 2005

Business Scope	\cdot Supports the development of pharmaceuticals, diagnostics, medical devices,
	biomarkers, and AI guided SaMD by utilizing imaging technologies
	· Clinical development support (monitoring, quality control, imaging core
	lab, image analysis, central imaging review, etc.)
	· PET tracer manufacturing support
	· Consulting for clinical development
	· Second-class marketing license for medical devices
URL	https://micron-kobe.com/en

Contact

Micron, Inc. INDICATE Group

E-mail	indicate@micron-kobe.com
--------	--------------------------